Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) insider Linda Llewelyn sold 6,442 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the transaction, the insider now directly owns 98,702 shares of the company's stock, valued at approximately $777,771.76. This trade represents a 6.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Linda Llewelyn also recently made the following trade(s):
- On Tuesday, October 15th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The shares were sold at an average price of $8.16, for a total value of $10,803.84.
Health Catalyst Stock Performance
Shares of NASDAQ:HCAT traded down $0.38 during trading on Wednesday, hitting $7.27. The stock had a trading volume of 575,392 shares, compared to its average volume of 561,162. The stock has a 50-day simple moving average of $8.16 and a two-hundred day simple moving average of $7.45. The stock has a market capitalization of $442.36 million, a price-to-earnings ratio of -5.39 and a beta of 1.31. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business's revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. On average, equities research analysts expect that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.
Institutional Trading of Health Catalyst
Hedge funds have recently modified their holdings of the stock. Primecap Management Co. CA lifted its holdings in Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company's stock valued at $15,205,000 after acquiring an additional 305,079 shares during the period. Janney Montgomery Scott LLC purchased a new position in shares of Health Catalyst during the 3rd quarter valued at approximately $897,000. Fred Alger Management LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at $6,858,000. Millrace Asset Group Inc. purchased a new stake in Health Catalyst during the third quarter worth $1,568,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Health Catalyst during the third quarter valued at $2,012,000. Hedge funds and other institutional investors own 85.00% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Wednesday, September 4th. Piper Sandler reiterated an "overweight" rating and set a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Royal Bank of Canada upped their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the company a "sector perform" rating in a research note on Thursday, November 7th. Finally, Citigroup lifted their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Health Catalyst currently has a consensus rating of "Moderate Buy" and an average target price of $11.79.
Get Our Latest Stock Report on HCAT
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
